CY1119308T1 - Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετου - Google Patents
Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετουInfo
- Publication number
- CY1119308T1 CY1119308T1 CY20171100902T CY171100902T CY1119308T1 CY 1119308 T1 CY1119308 T1 CY 1119308T1 CY 20171100902 T CY20171100902 T CY 20171100902T CY 171100902 T CY171100902 T CY 171100902T CY 1119308 T1 CY1119308 T1 CY 1119308T1
- Authority
- CY
- Cyprus
- Prior art keywords
- infections
- dab
- trp
- individual compounds
- diseases
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical class C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 abstract 2
- 208000035143 Bacterial infection Diseases 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000001860 Eye Infections Diseases 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 208000005141 Otitis Diseases 0.000 abstract 1
- 206010062255 Soft tissue infection Diseases 0.000 abstract 1
- 208000025609 Urogenital disease Diseases 0.000 abstract 1
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 1
- 230000017531 blood circulation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000019258 ear infection Diseases 0.000 abstract 1
- 208000011323 eye infectious disease Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000007914 intraventricular administration Methods 0.000 abstract 1
- 239000000816 peptidomimetic Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 206010040872 skin infection Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960004089 tigecycline Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12005744 | 2012-08-08 | ||
| PCT/EP2013/066530 WO2014023757A1 (en) | 2012-08-08 | 2013-08-07 | Combinations with a backbone-cyclized peptide |
| EP13745432.8A EP2882770B1 (en) | 2012-08-08 | 2013-08-07 | Combinations with a backbone-cyclized peptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119308T1 true CY1119308T1 (el) | 2018-02-14 |
Family
ID=46796226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171100902T CY1119308T1 (el) | 2012-08-08 | 2017-08-28 | Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετου |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9775877B2 (enExample) |
| EP (1) | EP2882770B1 (enExample) |
| JP (2) | JP6486270B2 (enExample) |
| KR (1) | KR102167324B1 (enExample) |
| CN (1) | CN104684925B (enExample) |
| AU (1) | AU2013301567B2 (enExample) |
| BR (1) | BR112015002727B1 (enExample) |
| CA (1) | CA2879207C (enExample) |
| CY (1) | CY1119308T1 (enExample) |
| DK (1) | DK2882770T3 (enExample) |
| EA (1) | EA030077B1 (enExample) |
| ES (1) | ES2639165T3 (enExample) |
| HR (1) | HRP20171299T1 (enExample) |
| HU (1) | HUE035891T2 (enExample) |
| IL (1) | IL236697B (enExample) |
| LT (1) | LT2882770T (enExample) |
| MX (2) | MX366997B (enExample) |
| NZ (1) | NZ703729A (enExample) |
| PL (1) | PL2882770T3 (enExample) |
| PT (1) | PT2882770T (enExample) |
| RS (1) | RS56249B1 (enExample) |
| SG (1) | SG11201500216TA (enExample) |
| SI (1) | SI2882770T1 (enExample) |
| WO (1) | WO2014023757A1 (enExample) |
| ZA (1) | ZA201500278B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602007008150D1 (de) | 2007-02-28 | 2010-09-09 | Polyphor Ltd | Templat-fixierte peptidomimetika |
| RS56249B1 (sr) * | 2012-08-08 | 2017-11-30 | Polyphor Ag | Kombinacije sa ciklizovanom okosnicom peptida |
| US20240100121A1 (en) * | 2020-11-23 | 2024-03-28 | Spexis Ag | Compositions of a beta-hairpin peptidomimetic and aerosol dosage forms thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527339T3 (es) | 2001-02-23 | 2015-01-23 | Polyphor Ltd. | Peptidomiméticos fijados a patrón con actividad antimicrobiana |
| WO2004018503A1 (en) | 2002-08-20 | 2004-03-04 | Polyphor Ltd. | Template-fixed peptidomimetics with antibacterial activity |
| WO2007079597A1 (en) * | 2006-01-16 | 2007-07-19 | Polyphor Ltd. | Template - fixed peptidomimetics with antimicrobial activity |
| DE602007008150D1 (de) * | 2007-02-28 | 2010-09-09 | Polyphor Ltd | Templat-fixierte peptidomimetika |
| WO2010017273A2 (en) * | 2008-08-06 | 2010-02-11 | Wyeth | Tigecycline formulations |
| RS56249B1 (sr) * | 2012-08-08 | 2017-11-30 | Polyphor Ag | Kombinacije sa ciklizovanom okosnicom peptida |
-
2013
- 2013-08-07 RS RS20170862A patent/RS56249B1/sr unknown
- 2013-08-07 EA EA201590351A patent/EA030077B1/ru unknown
- 2013-08-07 BR BR112015002727-0A patent/BR112015002727B1/pt not_active IP Right Cessation
- 2013-08-07 PL PL13745432T patent/PL2882770T3/pl unknown
- 2013-08-07 LT LTEP13745432.8T patent/LT2882770T/lt unknown
- 2013-08-07 SI SI201330760T patent/SI2882770T1/sl unknown
- 2013-08-07 EP EP13745432.8A patent/EP2882770B1/en active Active
- 2013-08-07 NZ NZ703729A patent/NZ703729A/en not_active IP Right Cessation
- 2013-08-07 CA CA2879207A patent/CA2879207C/en active Active
- 2013-08-07 HU HUE13745432A patent/HUE035891T2/en unknown
- 2013-08-07 ES ES13745432.8T patent/ES2639165T3/es active Active
- 2013-08-07 KR KR1020157005848A patent/KR102167324B1/ko active Active
- 2013-08-07 MX MX2015001685A patent/MX366997B/es active IP Right Grant
- 2013-08-07 WO PCT/EP2013/066530 patent/WO2014023757A1/en not_active Ceased
- 2013-08-07 SG SG11201500216TA patent/SG11201500216TA/en unknown
- 2013-08-07 JP JP2015525873A patent/JP6486270B2/ja not_active Expired - Fee Related
- 2013-08-07 US US14/419,986 patent/US9775877B2/en not_active Expired - Fee Related
- 2013-08-07 HR HRP20171299TT patent/HRP20171299T1/hr unknown
- 2013-08-07 CN CN201380041532.3A patent/CN104684925B/zh not_active Expired - Fee Related
- 2013-08-07 DK DK13745432.8T patent/DK2882770T3/en active
- 2013-08-07 PT PT137454328T patent/PT2882770T/pt unknown
- 2013-08-07 AU AU2013301567A patent/AU2013301567B2/en not_active Ceased
-
2015
- 2015-01-13 IL IL236697A patent/IL236697B/en active IP Right Grant
- 2015-01-14 ZA ZA2015/00278A patent/ZA201500278B/en unknown
- 2015-02-06 MX MX2019002657A patent/MX2019002657A/es unknown
-
2017
- 2017-08-28 CY CY20171100902T patent/CY1119308T1/el unknown
-
2018
- 2018-01-04 JP JP2018000089A patent/JP2018087191A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201791199A1 (ru) | Способ лечения болезни альцгеймера | |
| MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| PH12018500762A1 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| BR112018075300A2 (pt) | métodos para tratamento do mal de alzheimer | |
| BR112013007423A2 (pt) | terapia combinada no que diz respeito ao tratamento da infecção por hcv | |
| EP3590338A3 (en) | Medical treatments based on anamorelin | |
| EA201891007A1 (ru) | Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца | |
| MX2019007555A (es) | Uso de bacterias de acido láctico para tratar o prevenir la diabetes mellitus gestacional. | |
| CY1119308T1 (el) | Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετου | |
| CY1120727T1 (el) | Συνδυασμοι με ενα πεπτιδιο κυκλοποιημενου σκελετου | |
| CY1119073T1 (el) | Ισομορφες γλυκοζυλιωσης ανθρωπινης ιστικης καλλικρεινης 1 | |
| WO2016066722A3 (en) | Bacteriophage combinations for human or animal therapy | |
| PH12018501769A1 (en) | Medicament for treatment of diabetic foot infections | |
| BR112017009577A2 (pt) | análogos de pantotenamida | |
| EP3964215A4 (en) | Pharmaceutical composition, comprising 6-diazo-5-oxo-l-norleucine, for treatment of inflammatory skin disease | |
| CY1119845T1 (el) | Ενα γαλακτοκομικο προϊον μειωμενης χοληστερολης για χρηση στην θεραπευτικη αντιμετωπιση και/ή προληψη μιας ασθενειας του ηπατος | |
| BR112014016575A8 (pt) | método para o tratamento da doença de lyme | |
| RU2009119225A (ru) | Способ лечения и профилактики кокцидиозов норок | |
| EA202091647A1 (ru) | Соединения, композиции и способы лечения заболеваний, связанных с ацидозными или гипоксическими пораженными тканями | |
| RU2014104644A (ru) | Способ повышения эффективности лечения коров, больных острым гнойно-катаральным эндометритом | |
| UA102567U (uk) | Спосіб корекції імунної системи телят за умов антибіотикотерапії, при лікуванні респіраторних захворювань запального характеру | |
| TH158984A (th) | สารประกอบที่ออกฤทธิ์ในการรักษาและวิธีการใช้ของสารประกอบดังกล่าว | |
| EA201692163A1 (ru) | Лекарственное средство для лечения пациентов с тиннитусом | |
| EA201200407A1 (ru) | Новые терапевтические концепции лечения фибромиалгии |